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Abstract
Vertebral fracture risk is a heritable complex trait. The aim of this study was to identify genetic
susceptibility factors for osteoporotic vertebral fractures applying a genome-wide association
study (GWAS) approach. The GWAS discovery was based on the Rotterdam Study, a population-
based study of elderly Dutch individuals aged >55years; and comprising 329 cases and 2666
controls with radiographic scoring (McCloskey–Kanis) and genetic data. Replication of one top-
associated SNP was pursued by de-novo genotyping of 15 independent studies across Europe, the
United States, and Australia and one Asian study. Radiographic vertebral fracture assessment was
performed using McCloskey–Kanis or Genant semi-quantitative definitions. SNPs were analyzed
in relation to vertebral fracture using logistic regression models corrected for age and sex. Fixed
effects inverse variance and Han–Eskin alternative random effects meta-analyses were applied.
Genome-wide significance was set at p < 5 × 10−8. In the discovery, a SNP (rs11645938) on
chromosome 16q24 was associated with the risk for vertebral fractures at p=4.6×10−8. However,
the association was not significant across 5720 cases and 21,791 controls from 14 studies. Fixed-
effects meta-analysis summary estimate was 1.06 (95% CI: 0.98–1.14; p = 0.17), displaying high
degree of heterogeneity (I2=57%; Qhet p =0.0006). Under Han–Eskin alternative random effects
model the summary effect was significant (p = 0.0005). The SNP maps to a region previously
found associated with lumbar spine bone mineral density (LS-BMD) in two large meta-analyses
from the GEFOS consortium. A false positive association in the GWAS discovery cannot be
excluded, yet, the low-powered setting of the discovery and replication settings (appropriate to
identify risk effect size >1.25) may still be consistent with an effect size <1.10, more of the type
expected in complex traits. Larger effort in studies with standardized phenotype definitions is
needed to confirm or reject the involvement of this locus on the risk for vertebral fractures.
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Introduction
Vertebral fractures are the most common osteoporotic fractures and represent a significant
health issue [1,2]. Epidemiological measures derived from population-based studies vary
between 1 and 3% per year for incidence and ~10 and 30% for the prevalence in elderly
persons, varying by age, gender and geographic region [3-5]. Vertebral fractures are
associated with a high morbidity [6-11], mortality [12,13] and a considerable financial
burden. In the United States the costs of vertebral fractures were estimated to be 1.1 billion
dollars in the year 2005, and are expected to rise by more than 50% by the year 2025 [14]. A
recent report estimated the costs of vertebral fractures in Europe at 1.5billion euros in 2010
[15]. Furthermore, vertebral fractures are likely to become an increasingly important health
issue with the increasing age of populations [1,14,15] and their association with increased
risk of future osteoporotic fractures at other skeletal sites [7,16,17]. For all of these reasons,
a better understanding of the genetic susceptibility to vertebral fracture has the potential to
identify underlying biological mechanisms, improve risk prediction and lead to novel
disease interventions.
Vertebral fracture risk is a heritable complex trait, also influenced by environmental, and
gene–environment interactions [18,19]. A positive family history for vertebral fracture
constitutes an independent risk factor for future fractures [20], emphasizing the importance
of genetics in the pathogenesis of the disease. The hypothesis-free genome-wide association
study (GWAS) approach has been particularly successful in identifying loci associated with
many diseases and quantitative complex traits [21], including osteoporosis [18,22-24].
The aim of our study was to better understand the genetic architecture of radiographic
vertebral fractures by conducting the first GWAS for this trait in a large population-based
study of elderly Dutch individuals and pursuing replication in a large set of studies across
Europe, the United States, Australia and Asia.
Methods
Datasets assessed
Sample discovery phase—The discovery sample was confined to the original
Rotterdam Study cohort, a large population-based study of Dutch men and women aged 55
years and over (mean age at vertebral fracture assessment: 73.5 years). A detailed
description of the Rotterdam Study has been reported previously [25]. In short, the study
aimed to assess the incidence and determinants of disease and disability in elderly persons.
The study has been approved by the Medical Ethics Committee of the Erasmus University
Medical Center Rotterdam.
Sample replication phase—The Genetic Factors for Osteoporosis (GEFOS), Genetic
Markers for Osteoporosis (GENOMOS) and Anglo-Australasian Osteoporosis Genetics
Consortium (AOGC) are three consortia studying the genetic determinants of osteoporosis-
related skeletal phenotypes in populations with available DNA and/or GWAS data
[23,26-29]. Within this setting, 15 studies with both DNA samples and lateral morphometry-
derived vertebral fracture data participated in the replication phase of this project
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(Supplementary Table 1). More detailed descriptions are available in the Supplementary
material.
The AOGC – Geelong Osteoporosis Study (AOGC-GOS) is a cohort drawn from the
Geelong general population. Vertebral fracture imaging was performed in case of a clinical
indication [30,31]. The AOGC – Sheffield (AOGC-SHEFFIELD) study constitutes a large
population-based cohort of community-dwelling elderly women aged ≥75 years in Sheffield,
UK [32]. AROS (Aarhus Osteoporosis Study) is a case–control study, including 462
osteoporotic patients (vertebral fracture and T-score < −2.5) and 336 controls [33].
AUSTRIOS is a prospective cohort study of elderly female patients above 70 recruited in 95
nursing homes in four counties in Austria. The AUSTRIOS-B cohort had vertebral fracture
data available and was used for this project [34]. The Cantabria-Camargo (CABRIO-C) and
Cantabria Case–Control (CABRIO-CC) studies are based in Northern Spain. CABRIO-C is
a community-based study designed to evaluate the prevalence of metabolic bone diseases in
postmenopausal women and men older than 50 years attending a primary care center in
Santander [35,36]. CABRIO-CC is a clinic-based study of control individuals and patients
with osteoporosis living in Cantabria, a region in Northern Spain [37,38]. The Calcium
Intake Fracture Outcome Study (CAIFOS) is a randomized-controlled trial investigating
calcium carbonate supplementation in ambulatory women older than 70 years recruited in
Perth, Australia [39]. The Canadian Multicentre Osteoporosis Study (CaMoS) is a
population-based prospective cohort of unrelated men and women followed for osteoporosis
and osteoporotic fractures for the past 14 years [40-42]. The Danish Osteoporosis Prevention
Study (DOPS) is a population-based study of perimenopausal women. The women were
followed for 10years and approximately 35% were treated with hormone-replacement
therapy (HRT) [43]. The Edinburgh Osteoporosis Study (EDOS) consists of a clinical
referral population of patients assessed for evaluation of osteoporosis in Edinburgh, United
Kingdom. The European Prospective Osteoporosis Study (EPOS) is the prospective phase of
the European Vertebral Osteoporosis Study (EVOS) in which population-based samples had
paired duplicate spinal films. Men and women from 36 centers in 19 European countries
were recruited [5,44,45]. The Framingham Osteoporosis Study (FOS) is an ancillary study
of the Framingham Study, a multigenerational family-based cohort study originally initiated
to study the risk factors for cardiovascular disease [46-48]. Vertebral fracture assessment
was done on multidetector computed tomography (CT) lateral scout views. The Korean
osteoporosis study at Asan Medical Center (KorAMC) study is a hospital registered, cross-
sectional study of postmenopausal Korean women in Seoul [49]. The Longitudinal Aging
Study Amsterdam (LASA) is an ongoing multidisciplinary cohort study in older persons. A
random sample of men and women aged 55years and over, stratified by age, sex,
urbanization grade and expected 5-year mortality rate was drawn from the population
register of Amsterdam, The Netherlands [50]. The Osteoporotic Fractures in Men Sweden
(MrOS Sweden) study is a multicenter, prospective study including elderly men. Study
subjects (men aged 69–80 years) were randomly identified using national population
registers, contacted and asked to participate. Eligible subjects had to be able to walk without
assistance, provide self-reported data, and sign an informed consent [51]. The Prospective
Epidemiological Risk Factor (PERF) Study is based on subjects who were screened for or
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enrolled into randomized controlled clinical trial to identify genetic and other risk factors of
diseases in the elderly in Copenhagen, Denmark [52].
Phenotyping
Osteoporosis-related skeletal phenotypes in the discovery sample—During the
second follow-up visit between 1997 and 1999 all Rotterdam Study participants underwent
radiographic screening. A trained research technician obtained lateral radiographs of the
thoracolumbar spine following a standard protocol. Radiographs were evaluated
morphometrically in Sheffield, UK, by the McCloskey–Kanis method as described
previously [53]. Using this method, central collapse, anterior and posterior wedge, and crush
deformities were identified based on a cut point of 3 standard deviation height reductions.
All vertebral fractures were confirmed by visual interpretation by an expert in the field to
rule out artifacts and other etiologies, such as pathological fractures. Cases were defined as
those individuals who had at least one vertebral fracture, and controls were defined as those
who were free of vertebral fractures. Bone mineral density (BMD) of the femoral neck (FN)
and lumbar spine (LS) was measured by dual-energy X-ray absorptiometry (DXA), using a
Lunar DPX-L densitometer (Lunar Radiation Corporation, Madison, WI, USA).
Other measurements (covariates) in the discovery sample—An extensive
baseline home interview on medical history, risk factors for chronic diseases, and
medication use was performed on all participants by trained interviewers. Smoking habits
were coded as “current”, “former” and “never”. Self-reported age at natural menopause
between 40 and 60 years, defined as 12 months after periods ceased, was collected
retrospectively. Information on medication use included hormone replacement therapy and
systemic corticosteroids. Alcohol intake was assessed from a validated semi-quantitative
food-frequency questionnaire. Height and weight were measured with indoor clothing and
no shoes. Body mass index (BMI) was calculated as weight (in kg) / height (in m2).
Phenotyping replication phase—Vertebral fracture assessments differed by cohorts
which applied either the McCloskey–Kanis [53] or the Genant semi-quantitative method
[54]. Detailed description of the methods and cut-offs applied by each study is available in
Table 1. Four of the replication studies used the McCloskey–Kanis method, which is similar
to the discovery (Rotterdam Study), of which one study applied the same additional criterion
of absolute height reduction. Phenotyping for covariates was similar to that of the discovery
sample.
Genotyping
Genome-wide association data—The Rotterdam Study participants were genotyped
using the Illumina Infinium HumanHap550 Beadchip in the Genetic Laboratory of Erasmus
MC Department of Internal Medicine, The Netherlands, following manufacturers’ protocols
and quality control standards.
Single nucleotide polymorphism (SNP) genotyping—The top associated SNP from
the discovery phase (rs11645938) was genotyped in 15 studies within three main genotyping
centers: deCODE Genetics in Reykjavik, Iceland, Queensland University in Brisbane
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Australia and KBiosciences, Hertfordshire, U.K. (www.kbioscience.co.uk). Genotyping was
carried out by personnel blinded to patient status in all centers. The samples genotyped by
KBiosciences were part of the GENOMOS consortium DNA collection, and comprise most
of the participating studies. For KBiosciences, a minimum of 1.5μl of DNA at 3.3ng/μl
(when quantitated by PicoGreen analysis or 7 ng/μl if quantitated by spectrophotometry)
was required for one SNP to be assayed using their proprietary KASPar PCR technique and
Taqman (also used by Brisbane University for AOGC samples). Genotype calling was
carried out using an automated system, the results of which were checked manually by study
personnel using SNPviewer software (KBiosciences). deCODE used the same KASPar
assay from KBiosciences to genotype the PERF study samples. To ensure genotyping
validity across study centers, a reference plate was shipped from KBiosciences to the AOGC
coordinating center. To ensure correct genotyping deCODE Genetics genotyped 92 HapMap
samples for comparison with the KASPar assay, and both positive and negative samples
were present on all genotyping plates. Additionally, duplicate SNP genotyping was
performed in the Rotterdam Study (all samples) and CABRIO-C (random selection of 187
samples) and no discrepancies were found.
Statistical methods
Within the discovery cohort, we tested 2,543,887 genotyped or imputed (HapMap CEU
release 22, build 36) [55,56] SNPs for association with risk of osteoporotic vertebral
fractures using a logistic regression model (MACH2DAT) [57,58] adjusted for age, gender,
and admixture principal components (PCs) derived using EIGENSTRAT to adjust for
population substructure [59]. Potential effect modifiers for the relationship between
genotype and vertebral fracture (i.e. height, weight, BMI, age at menopause, HRT use,
corticosteroid use, >3 units alcohol use per day, current and ever smoking) were tested by
adding them one at a time to the regression model and evaluating the change in both the
effect estimate and significance. The GWAS was performed using a web-based interface
(GRIMP) on scalable super-computing grid infrastructures [60]. At a genome-wide
significant α-level of 5 × 10−8, the design had 0.80 power to detect risk effect sizes (OR) of
1.8 to 2.1 for minor allele frequencies (MAF) of 20% to 10%, respectively.
Replication analyses
Except for the FOS and AOGC studies, all analyses were carried out centrally by the
Rotterdam Coordinating Center. Again a logistic regression model adjusting for age and
gender was used. Individuals with either missing genotype or phenotype data were excluded
from analysis. Initially, fixed effects inverse variance meta-analysis was performed
(METAL software [61]). The presence of statistically significant heterogeneity was assessed
by Cochran’s Q statistic (Qhet p) and the extent of the observed heterogeneity was measured
by the I2 metric. Han–Eskin alternative random effects meta-analysis was applied when the
I2 metric exceeded 50% as this model is optimized to detect associations under
heterogeneity (Metasoft software [62]). SPSS 16.0, PLINK, and R software were used for
the rest of the analyses. In addition, the Framingham Study analysis used population-based
generalized estimating equation (GEE) approach correcting for correlations owing to family
relationships and PCs. The replication setting incorporating 5720 cases and 21,791 controls
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from 14 studies was powered to identify a variant with a MAF of 0.10 and risk effect size
>1.25, associated at p < 5×10−8.
Results
The description of the studies included in the discovery and replication phases is shown in
Supplementary Table 1. Description of the vertebral fracture assessment done across studies
is presented in Table 1 while baseline characteristics of the study populations are shown in
Supplementary Table 2. In the discovery set, 329 of the 2995 Rotterdam Study participants
had at least one vertebral fracture evident on the spinal radiographs. A genotyped SNP
(rs11645938) on chromosome 16q24 (MAF = 10%) was associated at a genome-wide
significant level (p = 4.6 × 10−8) with an increased risk of vertebral fractures (Fig. 1).
Compared to the risk of non-carriers, the odds of the heterozygous carriers of the minor
allele (C) was 1.7 times higher (95% confidence interval [CI] 1.3–2.3) and that of the
homozygous carriers was 5.8 times higher (95% CI 2.7–12.8) (Supplementary Fig. 1). Fig. 2
shows the regional association plot of the locus, where a cluster of FOX genes maps ~200
kb from the associated SNP, containing FOXF1, MTHFSD, FOXC2, and FOXL1. Further
adjusting for potential confounders did not influence either the effect estimate or the
significance of the association between genotype and vertebral fracture risk. Similarly, the
association remained significant after adjustment for either LS- or FN-BMD. Sex-stratified
association analysis for the SNP, showed similar effect estimates (OR heterozygote men: 1.8
[95% CI: 1.2–2.8] and OR heterozygote women: 1.6 [95% CI: 1.1–2.3]; OR homozygote
women: 8.4 [95% CI: 3.0–23.0] and OR homozygote men 3.3 [95% CI: 0.9–12.7]).
The associated SNP rs11645938 was successfully genotyped in 14 of the replication studies
(5722 vertebral fracture cases and 21,793 controls; MAF ~8–12%) while it was found to be
monomorphic in the Korean population of the KorAMC study (Table 2). The summary
effect estimate for vertebral fracture risk obtained from the meta-analysis was 1.06 (95% CI:
0.98–1.14; p=0.17) and the effect estimate displayed high degree of heterogeneity with
I2=57% and Qhet p =0.0006 (Fig. 3). When considering a Han–Eskin alternative random
effects meta-analysis model the summary effect was significant (p = 0.0005). When
applying more stringent genotyping criteria (call rate > 95%; Hardy–Weinberg equilibrium p
> 0.05) the association became significant in both the fixed (p=0.045) and Han–Eskin
alternative random effects meta-analysis (p=0.0002). When further restricting analyses only
to those studies that used the McCloskey–Kanis assessment a consistent, nonetheless not a
statistically significant, effect direction was observed (replication p=0.29).
Discussion
To our knowledge, this is the first GWAS for radiographically determined vertebral fracture.
A marker on chromosome 16q24 was genome-wide significantly associated with vertebral
fracture in the Rotterdam Study discovery set. However, this association was not significant
in a replication effort including 15 studies world-wide using conventional statistical analysis
techniques.
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Work by Stankiewicz et al. implicated deletions/mutations in this 16q24 locus in the
VACTERL association (Vertebral anomalies, Anal atresia, Cardiovascular anomalies,
TracheoEsophageal fistula, Renal and Radial anomalies, Limb defects), a non-random
association of birth defects that includes vertebral defects [63]. FOXC2, mapping ~200kb
upstream from the associated SNP, is highly expressed in human bone tissue, and its
expression is regulated by bone morphogenetic proteins [64]. The gene is involved in
osteoblast differentiation through activation of canonical Wnt/β-catenin signals [65], and in
mice Foxc2 functions as a transcription factor essential for axial skeletogenesis [66]. The
vertebral fracture associated SNP maps to a region previously found to be associated with
LS-BMD in a meta-analysis of 19,125 individuals [23] and further replicated in 83,894
individuals [22]. However, the vertebral fracture SNP was not associated with either LS- or
FN-BMD in our study and this signal was independent of the one previously reported for the
BMD SNP rs10048146 (r2 = 0.002).
Despite the underlying biological plausibility supporting this association and even with
identifying a genome-wide significant signal in the discovery GWAS, replication in
independent studies is still needed [21,67,68]. Subsequently, de-novo direct genotyping of
rs11645938 in 5720 cases and 21,791 controls, from multiple independent studies around
the world, did not provide robust evidence for replication of the association. Therefore, there
is a high likelihood of the signal being a false-positive signal. It is expected that discoveries
at underpowered settings would have low positive predictive value for true findings and this
applies even for signals that pass a stringent genome-wide significance threshold [69].
However, other considerations might have also contributed to an apparent lack of replication
of a potentially true association, and these will serve to inform the design of future GWAS
of the vertebral fracture phenotype.
Signals in underpowered settings are likely to display inflated effects due to the “winner’s
curse” phenomenon, where the effect estimate observed in the first study overestimates the
actual risk observed at the general population level [70-72]. According to a post-hoc
calculation for the replication phase, the current design had merely 0.42 power to detect an
OR of 1.2. The study sample should have included more than 8000 cases to achieve 0.80
power, and we know that typically GWAS of complex traits even requires close to 30,000
cases to identify truly associated SNPs with moderate allele frequencies (e.g. MAF = 0.10)
in a powered setting. Previous efforts have pointed out that SNPs with MAF <10% tend to
be difficult to replicate due to the lack of statistical power [78]. Thus, we cannot yet exclude
the possibility that the identified association has a very small, yet genuine effect [73].
Larger-scale GWAS meta-analyses for osteoporotic vertebral fractures are seriously needed.
GWA studies rely on the principle of linkage disequilibrium (LD) where markers are tested
under the assumption they tag an underlying causal genetic variant. When the linkage
disequilibrium structure in the region differs across populations this may result in decreased
power and lack of replication [74-77]. The rs11645938 marker is not in LD with any other
marker contained in HapMap and only in moderate LD with one marker (r2 = 0.41 with
rs11647070) from the 1000 Genomes Project. This observation led us to conclude that
existing GWAS without the rs11645938 on their arrays would be poorly imputed, which
was the case in the FOS and AOGC studies, and therefore to overcome this, de-novo
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genotyping of the marker was performed in these studies. However, strictly speaking,
genotyping in the Australian AOGC and CAIFOS studies did not attain conventional criteria
for unknown reasons. Further, the SNP is monomorphic in Asian populations.
Despite the fact that all studies used radiological assessments, a critical issue to bear in mind
is the phenotype definition, considering that diverse methods and cut-offs exist for the
assessment of vertebral fractures [79]. Phenotype measurement differences are a known
possible source of heterogeneity, which might be reflected in our study by the great variation
in vertebral fracture prevalences among the studies. Noticeably, prevalence estimates varied
between 6% and 49% in the cohort studies. Furthermore, quantitative scoring is based on
morphometry alone, which may result in inclusion of deformities into the phenotype
definition that are not truly vertebral fractures [80]. These non-fracture deformities are
frequently labeled as Genant grade 1 or “mild vertebral fractures,” when, in fact, they may
be normal variations in vertebral shape. Therefore, many studies assign an expert to filter
out these non-fracture deformities. Nevertheless, this triage procedure may not have been
sufficiently standardized, and this could have introduced the statistically significant
heterogeneity between studies. Several methods exist to explore the existence of
associations in heterogeneous data and when we applied a Han–Eskin random effects model,
more stringent genotyping criteria or sensitivity analyses for phenotype definition, the
results became more consistent. Perhaps selecting Genant grade 2 and 3 types including
“moderate” and “severe” vertebral fractures [81] could provide a better phenotype definition
for future genetic studies. In fact, Liu and colleagues demonstrated that the heritability of a
stricter phenotype (when only more severe deformities counted) was higher than considering
all vertebral deformities together [19]. Therefore, phenotype standardization among meta-
analysis participants can be a key in replication [71,82]. Unfortunately, data harmonization
was not possible because severity grading or qualitative standardized reading to enable data
harmonization was not available for most of the studies included in our analysis. This
consideration, along with the relatively small sample sizes across replication studies, is a
major hurdle to be overcome in future studies focusing on radiographic vertebral fractures.
Clinical vertebral fracture is an alternative phenotype definition for future genetic studies,
though achieving sufficient sample sizes will be also challenging; considering that only a
small fraction of vertebral fractures come to clinical attention (i.e. are symptomatic). In
addition, it would be valuable to gain more insight into incident vertebral fractures.
Nevertheless, definition of incident vertebral fractures is accompanied by different and
possibly greater precision errors than identification of prevalent vertebral fractures. On the
other hand, by comparing images at different follow-ups, the radiological reader has the
opportunity to correct possible misclassifications, including misattributions of baseline
deformities as fracture cases caused by erroneous vertebral height readings due to for
example superimposition of other structures or magnification errors [83-86].
In conclusion, although a GWAS in the population-based Rotterdam Study identified a
marker mapping to the 16q24 (FOXC2) BMD locus as being genome-wide significantly
associated with radiographic vertebral fracture in that population, this could not be
conclusively replicated by de-novo genotyping across 15 studies worldwide. A false positive
association in the GWAS discovery cannot yet be excluded. However, these results from a
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low-powered setting may still be consistent with a small true effect size as is common in
complex traits. Larger efforts in subsequent GWAS for radiographic vertebral fracture with
standardized phenotype definitions may confirm or reject the involvement of this locus on
the risk for vertebral fractures.
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GENOMOS Genetic Markers for Osteoporosis
AOGC Anglo-Australasian Osteoporosis Genetics Consortium
AOGC-GOS Anglo-Australasian Osteoporosis Genetics Consortium — Geelong
Osteoporosis Study
AROS Aarhus Osteoporosis Study
CABRIO-C Cantabria-Camargo study
CABRIO-CC Cantabria Case–Control study
CAIFOS Calcium Intake Fracture Outcome Study
CaMoS Canadian Multicentre Osteoporosis Study
DOPS Danish Osteoporosis Prevention Study
HRT hormone-replacement therapy
EDOS Edinburgh Osteoporosis Study
EPOS European Prospective Osteoporosis Study
EVOS European Vertebral Osteoporosis Study
FOS Framingham Osteoporosis Study
CT computed tomography
KorAMC Korean osteoporosis study at Asan Medical Center
LASA Longitudinal Aging Study Amsterdam
MrOS Sweden Osteoporotic Fractures in Men Sweden
PERF Prospective Epidemiological Risk Factor
FN femoral neck
LS lumbar spine
DXA dual-energy X-ray absorptiometry
BMI body mass index
OR odds ratio
MAF minor allele frequency
PCs principal components
GEE generalized estimating equation
VACTERL Vertebral anomalies, Anal atresia, Cardiovascular anomalies,
TracheoEsophageal fistula, Renal and Radial anomalies, Limb defects
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Fig. 1.
Manhattan plot of negative logarithm p-values plotted by chromosome, showing that a SNP
on chromosome 16q24 was associated at a genome-wide significant level with osteoporotic
vertebral fractures (p=4.6 × 10−8) in the Rotterdam Study (encircled).
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Fig. 2.
Regional association plot showing position on chromosome 16 and association p-values of
the analyzed SNPs in the Rotterdam Study with neighboring genes. Included are genotyped,
HapMap II and 1000 Genomes imputed SNPs. The rectangle is the SNP of interest, and the
circles represent neighboring SNPs with their respective correlation with the top marker.
The spikes depict the recombination rates. The position of the rs10048146 SNP that has
previously been found as associated with lumbar-spine bone mineral density is indicated
with *.
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Fig. 3.
Forest plot showing meta-analysis results of vertebral fracture risk for rs11645938 in
discovery and replication studies. Effect estimates represented by squares are displayed on a
logarithmic scale, with horizontal lines corresponding to 95% confidence intervals. The
center line of the diamond stands for the overall summary measure, and its horizontal line
indicates the 95% confidence interval.
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